. "15" . . . . . "Mus\u00ED doch\u00E1zet ke zvy\u0161ov\u00E1n\u00ED hmotnosti u nemocn\u00FDch s diabetes mellitus 2. typu po zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby?. \u010D\u00E1st II.,. V\u00FDsledky studie KILOS" . "[C40FF1101DAB]" . "RIV/00064203:_____/13:10193940" . . "C\u00CDL PR\u00C1CE: Prim\u00E1rn\u00EDm c\u00EDlem prodlou\u017Een\u00E9 studie KILOS II bylo dal\u0161\u00ED 12m\u011Bs\u00ED\u010Dn\u00ED sledov\u00E1n\u00ED zm\u011Bn hmotnosti nemocn\u00FDch s DM2 p\u016Fvodn\u011B l\u00E9\u010Den\u00FDch inzulinem (mimo detemir) nejm\u00E9n\u011B 12 m\u011Bs\u00EDc\u016F a pot\u00E9 p\u0159eveden\u00FDch na l\u00E9\u010Dbu inzulinov\u00FDm analogem detemir tak\u00E9 po dobu 12 m\u011Bs\u00EDc\u016F. Sekund\u00E1rn\u00EDm c\u00EDlem studie bylo sledov\u00E1n\u00ED zm\u011Bn glykovan\u00E9ho hemoglobinu ve stejn\u00FDch \u010Dasov\u00FDch period\u00E1ch. MATERI\u00C1L A METODY: Celkem byla z\u00EDsk\u00E1na data od 168 (z p\u016Fvodn\u00EDch 206) nemocn\u00FDch s DM 2. typu. V prodlou\u017Een\u00E9m sledov\u00E1n\u00ED byly zaznamen\u00E1v\u00E1ny stejn\u00E9 \u00FAdaje jako ve studii KILOS I - hmotnost, d\u00E1vky inzulinu a HbA1c ve 3m\u011Bs\u00ED\u010Dn\u00EDch intervalech. V\u00DDSLEDKY: Ve druh\u00E9m roce sledov\u00E1n\u00ED do\u0161lo u na\u0161eho souboru k dal\u0161\u00EDmu sn\u00ED\u017Een\u00ED BMI (o -0,37) a sn\u00ED\u017Een\u00ED hmotnosti o v\u00EDce ne\u017E 1 kg bylo zaznamen\u00E1no u 50,9 % souboru, zat\u00EDmco zv\u00FD\u0161en\u00ED hmotnosti o v\u00EDce ne\u017E 1 kg bylo potvrzeno u 19,2 % sledovan\u00FDch. Kompenzace diabetu dle HbA1c se statisticky v\u00FDznamn\u011B nezm\u011Bnila, stejn\u011B jako pr\u016Fm\u011Brn\u00E9 denn\u00ED d\u00E1vky inzul\u00EDnu."@cs . "RIV/00064203:_____/13:10193940!RIV14-MZ0-00064203" . "C\u00CDL PR\u00C1CE: Prim\u00E1rn\u00EDm c\u00EDlem prodlou\u017Een\u00E9 studie KILOS II bylo dal\u0161\u00ED 12m\u011Bs\u00ED\u010Dn\u00ED sledov\u00E1n\u00ED zm\u011Bn hmotnosti nemocn\u00FDch s DM2 p\u016Fvodn\u011B l\u00E9\u010Den\u00FDch inzulinem (mimo detemir) nejm\u00E9n\u011B 12 m\u011Bs\u00EDc\u016F a pot\u00E9 p\u0159eveden\u00FDch na l\u00E9\u010Dbu inzulinov\u00FDm analogem detemir tak\u00E9 po dobu 12 m\u011Bs\u00EDc\u016F. Sekund\u00E1rn\u00EDm c\u00EDlem studie bylo sledov\u00E1n\u00ED zm\u011Bn glykovan\u00E9ho hemoglobinu ve stejn\u00FDch \u010Dasov\u00FDch period\u00E1ch. MATERI\u00C1L A METODY: Celkem byla z\u00EDsk\u00E1na data od 168 (z p\u016Fvodn\u00EDch 206) nemocn\u00FDch s DM 2. typu. V prodlou\u017Een\u00E9m sledov\u00E1n\u00ED byly zaznamen\u00E1v\u00E1ny stejn\u00E9 \u00FAdaje jako ve studii KILOS I - hmotnost, d\u00E1vky inzulinu a HbA1c ve 3m\u011Bs\u00ED\u010Dn\u00EDch intervalech. V\u00DDSLEDKY: Ve druh\u00E9m roce sledov\u00E1n\u00ED do\u0161lo u na\u0161eho souboru k dal\u0161\u00EDmu sn\u00ED\u017Een\u00ED BMI (o -0,37) a sn\u00ED\u017Een\u00ED hmotnosti o v\u00EDce ne\u017E 1 kg bylo zaznamen\u00E1no u 50,9 % souboru, zat\u00EDmco zv\u00FD\u0161en\u00ED hmotnosti o v\u00EDce ne\u017E 1 kg bylo potvrzeno u 19,2 % sledovan\u00FDch. Kompenzace diabetu dle HbA1c se statisticky v\u00FDznamn\u011B nezm\u011Bnila, stejn\u011B jako pr\u016Fm\u011Brn\u00E9 denn\u00ED d\u00E1vky inzul\u00EDnu." . "Must the start of insulin treatment in type 2 diabetes patients be connected with increasing of their body weight?"@en . "Mus\u00ED doch\u00E1zet ke zvy\u0161ov\u00E1n\u00ED hmotnosti u nemocn\u00FDch s diabetes mellitus 2. typu po zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby?. \u010D\u00E1st II.,. V\u00FDsledky studie KILOS"@cs . "Peru\u0161i\u010Dov\u00E1, Jind\u0159i\u0161ka" . "1"^^ . . . . "1"^^ . "HbA; BMI; detemir; insulin"@en . "Mus\u00ED doch\u00E1zet ke zvy\u0161ov\u00E1n\u00ED hmotnosti u nemocn\u00FDch s diabetes mellitus 2. typu po zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby?. \u010D\u00E1st II.,. V\u00FDsledky studie KILOS" . "90220" . . "CZ - \u010Cesk\u00E1 republika" . "5"^^ . . "1212-7299" . "http://www.internimedicina.cz/pdfs/int/2013/01/12.pdf" . "Must the start of insulin treatment in type 2 diabetes patients be connected with increasing of their body weight?"@en . "1" . "Intern\u00ED medic\u00EDna pro praxi" . . . . . . "I" . "Mus\u00ED doch\u00E1zet ke zvy\u0161ov\u00E1n\u00ED hmotnosti u nemocn\u00FDch s diabetes mellitus 2. typu po zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby?. \u010D\u00E1st II.,. V\u00FDsledky studie KILOS"@cs . "BACKGROUND AND AIMS: The primary objective of the extended study KILOS I (=KILOS II) was to evaluate the change in body weight and BMI during next 12 months on insulin detemir treatment and to compare it with the changes in body weight and BMI during the previous 12 months of detemir treatment following another basal insulin (NPH, glargin) treatment. The secondary objective of the study was to evaluate the changes in glycaemic control measured by HbA1c. MATERIALS AND METHODS: This study was a 17-sites, open, not controlled, observational. Data of 168 patients with type 2 diabetes from study KILOS I were collected. In extended study the basic data of patients were recorded next 12 month. CONCLUSION: The weight of patients increased on the average by 2,11 kg before change of basal insulin therapy to detemir in one year. Weight decreased by 1,82 kg per year on the average after switch to detemir and still decreased durin 1 years of extended study by -0,82 kg. Mean drop in HbA1c value was -0.54% and patients hold on the same value during 1 year of extended study."@en .